Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a ...

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and ...

Teva Pharmaceuticals TEVA announced a funding agreement with Royalty Pharma plc RPRX, under which the latter will provide up ...

Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties Royalty Pharma maintained industry leadership ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...

Royalty Pharma's board has raised the biopharmaceutical royalties investor's quarterly dividend by 6.8%, to 23.5 cents from 22 cents. The new payout, equal to 94 cents a year, represents an annual ...

Xoma argued Janssen breached the contract Xoma had with the third-party pharmaceutical company, as well as the contract the ...

While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A ...

Royalty Pharma Evrysdi royalty acquisition completed for $240M. RPRX now owns 100% of the tiered royalty on Roche's SMA drug, ...

Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.